1. Home
  2. IOVA vs SMWB Comparison

IOVA vs SMWB Comparison

Compare IOVA & SMWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • SMWB
  • Stock Information
  • Founded
  • IOVA 2007
  • SMWB 2007
  • Country
  • IOVA United States
  • SMWB Israel
  • Employees
  • IOVA N/A
  • SMWB N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • SMWB Computer Software: Programming Data Processing
  • Sector
  • IOVA Health Care
  • SMWB Technology
  • Exchange
  • IOVA Nasdaq
  • SMWB Nasdaq
  • Market Cap
  • IOVA 771.4M
  • SMWB 654.9M
  • IPO Year
  • IOVA N/A
  • SMWB 2021
  • Fundamental
  • Price
  • IOVA $1.88
  • SMWB $8.28
  • Analyst Decision
  • IOVA Buy
  • SMWB Strong Buy
  • Analyst Count
  • IOVA 10
  • SMWB 8
  • Target Price
  • IOVA $12.22
  • SMWB $15.75
  • AVG Volume (30 Days)
  • IOVA 10.4M
  • SMWB 502.8K
  • Earning Date
  • IOVA 08-07-2025
  • SMWB 08-05-2025
  • Dividend Yield
  • IOVA N/A
  • SMWB N/A
  • EPS Growth
  • IOVA N/A
  • SMWB N/A
  • EPS
  • IOVA N/A
  • SMWB N/A
  • Revenue
  • IOVA $212,679,000.00
  • SMWB $258,017,999.00
  • Revenue This Year
  • IOVA $86.62
  • SMWB $16.87
  • Revenue Next Year
  • IOVA $69.95
  • SMWB $14.96
  • P/E Ratio
  • IOVA N/A
  • SMWB N/A
  • Revenue Growth
  • IOVA 11070.12
  • SMWB 15.06
  • 52 Week Low
  • IOVA $1.64
  • SMWB $5.71
  • 52 Week High
  • IOVA $12.51
  • SMWB $17.64
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 47.47
  • SMWB 53.68
  • Support Level
  • IOVA $1.68
  • SMWB $8.53
  • Resistance Level
  • IOVA $2.02
  • SMWB $9.19
  • Average True Range (ATR)
  • IOVA 0.11
  • SMWB 0.44
  • MACD
  • IOVA 0.03
  • SMWB 0.06
  • Stochastic Oscillator
  • IOVA 61.42
  • SMWB 56.84

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About SMWB Similarweb Ltd.

Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.

Share on Social Networks: